Education
About Us
Working with TipRanks
Follow Us
Immunitybio Inc (IBRX)
:IBRX
IBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.83 - $7.48
Previous CloseN/A
Volume1.20M
Average Volume (3M)7.09M
Market Cap
$2.33B
Enterprise Value$3.03B
Total Cash (Recent Filing)$153.66M
Total Debt (Recent Filing)$535.32M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 07, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding945,254,700
10 Day Avg. Volume6,816,317
30 Day Avg. Volume7,092,315
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue53.62
Enterprise Value/Gross Profit53.80
Enterprise Value/Ebitda-16.63
Forecast
1Y Price Target
$5.33Price Target Upside89.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical DataUpdated data from the QUILT-3.032 trial showed that ANKTIVA plus BCG led to a 58.2% disease-free survival rate at 12 months in patients with BCG-unresponsive NMIBC and papillary disease without CIS.
Earnings GrowthANKTIVA's sales reached $26.4M, reflecting 60% quarter-over-quarter growth, driven by increasing adoption in U.S. urology practices.
Regulatory ApprovalsThe U.K. approval marks a key international milestone for Anktiva, representing a significant step in ImmunityBio's global strategy and affirming the strength of Anktiva’s underlying data.
Bears Say
Regulatory ChallengesThe FDA raised concerns about the single-arm design of the QUILT-3.032 Cohort B study during the Type A meeting regarding ANKTIVA’s supplemental BLA.
Regulatory DelaysImmunityBio announced it received a surprising Refusal to File (RTF) letter from the FDA regarding its supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC patients with papillary-only disease.
Regulatory UncertaintyThe RTF letter introduces regulatory uncertainty, despite the identical treatment protocol between CIS and papillary cohorts.
ImmunityBio News
IBRX FAQ
What was Immunitybio Inc’s price range in the past 12 months?
Immunitybio Inc lowest stock price was $1.83 and its highest was $7.48 in the past 12 months.
What is Immunitybio Inc’s market cap?
Immunitybio Inc’s market cap is $2.33B.
When is Immunitybio Inc’s upcoming earnings report date?
Immunitybio Inc’s upcoming earnings report date is Nov 07, 2025 which is in 84 days.
How were Immunitybio Inc’s earnings last quarter?
Immunitybio Inc released its earnings results on Aug 05, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.108 by $0.008.
Is Immunitybio Inc overvalued?
According to Wall Street analysts Immunitybio Inc’s price is currently Undervalued.
Does Immunitybio Inc pay dividends?
Immunitybio Inc does not currently pay dividends.
What is Immunitybio Inc’s EPS estimate?
Immunitybio Inc’s EPS estimate is -0.11.
How many shares outstanding does Immunitybio Inc have?
Immunitybio Inc has 945,254,700 shares outstanding.
What happened to Immunitybio Inc’s price movement after its last earnings report?
Immunitybio Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.108. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunitybio Inc?
Currently, no hedge funds are holding shares in IBRX
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.33 (89.01% Upside)
$5.33 (89.01% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
78.99%
Trailing 12-Months
Asset Growth
-9.51%
Trailing 12-Months
Company Description
Immunitybio Inc
ImmunityBio (IBRX) is a biotechnology company focused on developing innovative immunotherapy treatments aimed at activating the immune system to fight cancer and infectious diseases. The company specializes in harnessing the power of the immune system through platforms such as its proprietary T-cell and natural killer (NK) cell therapies, along with various vaccine candidates designed to enhance immune responses. Their core products include treatments for solid tumors and other cancers, as well as therapies targeting infectious diseases like COVID-19.
IBRX Stock 12 Month Forecast
Average Price Target
$5.33
▲(89.01% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
74.12% Insiders
2.86% Mutual Funds
0.04% Other Institutional Investors
18.80% Public Companies and
Individual Investors